Patents Assigned to Thrombosis Research Institute
-
Patent number: 11332515Abstract: The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products.Type: GrantFiled: January 25, 2016Date of Patent: May 17, 2022Assignee: THROMBOSIS RESEARCH INSTITUTEInventors: Vijay Kakkar, Xinjie Lu
-
Patent number: 10709796Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.Type: GrantFiled: July 17, 2017Date of Patent: July 14, 2020Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
-
Patent number: 9764045Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.Type: GrantFiled: April 7, 2015Date of Patent: September 19, 2017Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John Mcvey, John Gray, Andrew Davidoff
-
Patent number: 9393323Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.Type: GrantFiled: July 8, 2010Date of Patent: July 19, 2016Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
-
Patent number: 8435538Abstract: The invention relates to a recombinant protein comprising: a carrier portion; a first epitope capable of eliciting an anti-atheroma response; and a second epitope capable of eliciting an anti-atheroma response, characterized in that said first and second epitopes are distinct from one another.Type: GrantFiled: April 14, 2009Date of Patent: May 7, 2013Assignee: Thrombosis Research InstituteInventors: Vijay Kakkar, Xinjie Lu
-
Publication number: 20130024960Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.Type: ApplicationFiled: July 8, 2010Publication date: January 24, 2013Applicants: UCL BUSINESS PLC, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THROMBOSIS RESEARCH INSTITUTEInventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
-
Publication number: 20090252765Abstract: The invention relates to a recombinant Mycobacterium bovis which expresses at least one Chlamydophila pneumoniae antigen.Type: ApplicationFiled: May 16, 2008Publication date: October 8, 2009Applicants: Thrombosis Research Institute, University of SzegedInventors: Katalin Burian, Valeria Endresz, Vijay Kakkar, Xinjie Lu, Andras Miczak
-
Patent number: 5648338Abstract: Peptides which act as inhibitors or substrates of thrombin are derived from the formula: D-Phe-Pro-Arg or its analogues, wherein Phe is substituted by (a), wherein Ar.sub.1 or Ar.sub.2 are the same or different and are selected from the group consisting of phenyl, thienyl, pyridyl, naphthyl, thionaphtyl, indolyl and saturated groups corresponding to these, optionally substituted by up to three groups selected from C.sub.1 -C.sub.3 alkyl and C.sub.1 -C.sub.3 alkoxy, L.sub.1 and L.sub.2 are the same of different and are selected from the group consisting of CH.sub.2, C.sub.2 --C.sub.2, O-CH.sub.2, S-CH.sub.2, Ar-L taken together optionally means H, diphenyl-methyl, fluorenyl or saturated groups corresponding to these, but one of the Ar-L cannot be H when the other [CH.sub.2 ].sub.n -Q, (c) where Q=H, amino, amidino, imidazole, guanidino or isothioureido and n=1-5, preferably 3-5, or C.sub.3 -C.sub.9 alkyl and C.sub.5 -C.sub.Type: GrantFiled: October 4, 1994Date of Patent: July 15, 1997Assignee: Thrombosis Research InstituteInventors: Vijay Vir Kakkar, John Joseph Deadman, Goran Karl Claeson, Leifeng Cheng, Naoyashi Chino, Said Mohamed Anwar Elgendy, Michael Finbarr Scully
-
Patent number: 5596123Abstract: Stable .alpha.-substituted boronic esters, e.g. for use in peptide synthesis, are prepared by reacting a substituted alkene of the formula: ##STR1## with a disubstituted borane of the formula: ##STR2## wherein: (i) R.sup.1 and R.sup.2 are each selected from various groups which are preferably not leaving groups;(ii) X is halogen or other leaving group;(iii) Y is H or lower alkyl;(iv) Q.sup.1 and Q.sup.2 are each selected from various groups which are preferably such that the borane is non-hydrolyzable, and particularly Q.sup.1 and Q.sup.2 together may represent a residue of a diol such as catechol or pinanediol.Type: GrantFiled: June 2, 1995Date of Patent: January 21, 1997Assignee: Thrombosis Research InstituteInventors: Said M. A. Elgendy, John J. Deadman, Geeta Patel, Donovan S. Green, Jehan A. Baban, Vijay V. Kakkar, Goran K. Claeson
-
Patent number: 5576304Abstract: A pharmaceutical composition comprising dermatan sulphate, together with a low molecular weight heparin, free or fixed combination, is useful as a antithrombolytic agent with a low risk of bleeding complications.Type: GrantFiled: July 9, 1991Date of Patent: November 19, 1996Assignee: Thrombosis Research InstituteInventors: Vijay V. Kakkar, Michael F. Scully
-
Patent number: 5574014Abstract: Pharmaceutical compositions comprising compounds of the formula: ##STR1## in which X=H or is an N-protecting group; Y is Phe-Pro; Q1 and Q2 taken together represent the residue of a diol; R is C.sub.1-4 alkyl; and the asymmetric carbon atom marked * may have the D- or L- configuration, are useful in therapeutic methods of inhibiting thrombin.Type: GrantFiled: May 10, 1994Date of Patent: November 12, 1996Assignee: Thrombosis Research InstituteInventors: Goran Claeson, Manfred H. W. Philipp, Rainer Metternich